Leucemia mieloide aguda con afectación neurológica y mamaria durante el embarazo. Reporte de un caso

IF 0.1 Q4 ONCOLOGY

Gaceta Mexicana de Oncologia Pub Date : 2016-03-01 DOI:10.1016/j.gamo.2016.01.001

Mercedes del Pilar Álvarez-Goris , Juan Carlos Fuentes-Cobos , Nidia Carolina Espinosa Maldonado , Ricardo Sánchez Zamora , Angélica Ariadna Torres Aguilar , Ángel Augusto Pérez Calatayud , Jesús Carlos Briones Garduño

{"title":"Leucemia mieloide aguda con afectación neurológica y mamaria durante el embarazo. Reporte de un caso","authors":"Mercedes del Pilar Álvarez-Goris , Juan Carlos Fuentes-Cobos , Nidia Carolina Espinosa Maldonado , Ricardo Sánchez Zamora , Angélica Ariadna Torres Aguilar , Ángel Augusto Pérez Calatayud , Jesús Carlos Briones Garduño","doi":"10.1016/j.gamo.2016.01.001","DOIUrl":null,"url":null,"abstract":"<div><p>The diagnosis of leukaemia is very rare during pregnancy, with a prevalence of 1:75,000 to 100,000 pregnant women. Around two-thirds are myeloid type, and it is characterised by a fast and lethal progression without early treatment. After early diagnosis, the chemotherapy should be established immediately to ensure the life of the mother. Although there are a few cases reports of good outcomes in second trimester, there are many adverse effects in the foetus in first trimester, making it a huge therapeutic dilemma. The patient will require interdisciplinary management, including haematology, obstetrics, and oncology. In particular they will also need to be informed about the importance in the timing of early chemotherapy and the inherent risks in pregnancy, as well as the risks of deciding not to interrupt it. The information on the diagnosis and treatment of acute myeloid leukaemia in pregnancy is limited in world literature.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 2","pages":"Pages 98-102"},"PeriodicalIF":0.1000,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.01.001","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gaceta Mexicana de Oncologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S166592011600002X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The diagnosis of leukaemia is very rare during pregnancy, with a prevalence of 1:75,000 to 100,000 pregnant women. Around two-thirds are myeloid type, and it is characterised by a fast and lethal progression without early treatment. After early diagnosis, the chemotherapy should be established immediately to ensure the life of the mother. Although there are a few cases reports of good outcomes in second trimester, there are many adverse effects in the foetus in first trimester, making it a huge therapeutic dilemma. The patient will require interdisciplinary management, including haematology, obstetrics, and oncology. In particular they will also need to be informed about the importance in the timing of early chemotherapy and the inherent risks in pregnancy, as well as the risks of deciding not to interrupt it. The information on the diagnosis and treatment of acute myeloid leukaemia in pregnancy is limited in world literature.

查看原文本刊更多论文

妊娠期伴有神经和乳腺损伤的急性髓系白血病。报告个案

在怀孕期间诊断出白血病是非常罕见的，发病率为1:7万5千至10万名孕妇。大约三分之二是骨髓型，其特点是如果不及早治疗，病情发展迅速且致命。在早期诊断后，应立即确定化疗方案，以确保母亲的生命。虽然在妊娠中期有少数病例报告有良好的结果，但在妊娠早期胎儿有许多不良反应，使其成为一个巨大的治疗困境。患者将需要跨学科的管理，包括血液学、产科和肿瘤学。特别是，她们还需要被告知早期化疗时机的重要性和妊娠期的内在风险，以及决定不中断化疗的风险。关于妊娠期急性髓性白血病的诊断和治疗的信息在世界文献中是有限的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gaceta Mexicana de Oncologia ONCOLOGY-

CiteScore

0.10

自引率

0.00%

发文量

255